Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-08-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
监事会决议公告
Board/Management Information Classification · 90% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the approval of the company's 2023 semi-annual report and related special reports on fundraising and non-recurring fund occupation. The document is short (1037 characters) and primarily announces the passing of resolutions rather than containing the full semi-annual report or detailed financial data. It explicitly states the approval of the 2023 semi-annual report and related reports but does not include the reports themselves. Therefore, this document is an announcement of meeting resolutions related to management and supervisory board decisions, not the actual interim report or financial statements. Given the nature of the content, it fits best under Board/Management Information (MANG) as it relates to supervisory board meeting resolutions and approvals.
2023-08-28 Chinese
第六届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of 康芝药业股份有限公司 regarding the resolution passed in their sixth meeting of the sixth supervisory board. It details the approval of a restricted stock incentive plan, including the number of shares granted and the eligibility of the recipients. The document is short (1190 characters) and primarily serves as an official announcement of a board decision related to management incentives. It does not contain financial statements, audit information, or detailed financial data. It is not a report or presentation but a formal announcement of a board/management decision. Therefore, it fits best under Board/Management Information (MANG).
2023-06-30 Chinese
监事会关于2023年限制性股票激励计划激励对象名单（截至授予日）的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the supervisory board of Kangzhi Pharmaceutical Co., Ltd. regarding the verification opinion on the list of incentive recipients for the 2023 restricted stock incentive plan. It includes legal references, compliance checks, and approval of the stock incentive grant. The content focuses on the approval and verification of the stock incentive plan participants and the grant details, which is typical of a Capital/Financing Update related to equity incentives. The document is short (1358 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of voting results, but a specific update on capital structure via stock incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-06-30 Chinese
关于向激励对象授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of restricted stock under a 2023 stock incentive plan by 康芝药业股份有限公司. It includes specifics such as the grant date, number of shares, recipients, performance conditions, approval procedures, legal and financial advisor opinions, and compliance with regulatory requirements. The content focuses on the stock incentive plan and its implementation rather than financial results or management changes. This type of document is a formal announcement of a capital-related event, specifically a share-based compensation plan involving issuance of restricted shares to employees and executives. It does not contain financial statements or earnings data, nor is it a report or transcript. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through stock incentives.
2023-06-30 Chinese
独立董事关于第六届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a board meeting agenda item related to a stock incentive plan. It references compliance with regulatory rules and company bylaws, and provides an independent judgment on the stock incentive grant. It is not a full financial report, earnings release, or regulatory filing but rather a formal opinion related to board/management matters. The content focuses on governance and management decisions regarding stock incentives, which aligns with Board/Management Information filings.
2023-06-30 Chinese
关于康芝药业股份有限公司2023年限制性股票激励计划授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 restricted stock incentive plan grant matters of Kangzhi Pharmaceutical Co., Ltd. It discusses the legal compliance, approval, authorization, and conditions related to the stock incentive plan. The document is not a financial report, earnings release, or management discussion but a legal opinion related to a capital incentive plan. It is not a simple announcement but a detailed legal opinion letter. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and stock incentive plans, not a direct financial report or management report. The document length and content confirm it is not a brief announcement or a proxy statement but a legal opinion letter. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.